Physician profile
Dan Popescu
NPI 1932102696
$3,796.33
in general payments reported to CMS, 2019-2025
31 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,052 · 2020: $100 · 2021: $108 · 2024: $333 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.55 |
| Education | $143.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $1,901.60 | 2019 | |
| Genentech USA, INC. | $213.96 | 2019-2024 | Tecentriq Hybreza, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $169.26 | 2019-2025 | Enhertu |
| Incyte Corporation | $144.24 | 2019-2024 | |
| Puma Biotechnology, INC. | $124.00 | 2019 | |
| Pfizer INC. | $116.10 | 2019-2024 | |
| Janssen Biotech, INC. | $113.69 | 2019-2025 | Rybrevant |
| Daiichi Sankyo INC. | $108.54 | 2024-2025 | Enhertu, Datroway |
| Ipsen Biopharmaceuticals, INC | $107.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.48 | 2019-2025 | Opdivo |
| Seagen INC. | $76.08 | 2019 | |
| Celgene Corporation | $74.33 | 2019 | |
| Merck Sharp & Dohme LLC | $69.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.75 | 2019-2024 | |
| Amgen INC. | $50.28 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.02 | 2019 | |
| Abbvie INC. | $39.83 | 2024 | |
| Astellas Pharma US INC | $36.40 | 2019-2025 | Vyloy |
| Genzyme Corporation | $35.44 | 2019 | |
| Glaxosmithkline, LLC. | $29.70 | 2024 | Jemperli |
| Amag Pharmaceuticals, INC. | $26.60 | 2019 | |
| Fresenius Kabi USA, LLC | $25.00 | 2025 | |
| Eisai INC. | $23.06 | 2019 | |
| Lilly USA, LLC | $19.04 | 2024 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.22 | 2019 | |
| Gilead Sciences, INC. | $15.87 | 2019 | |
| Exelixis INC. | $13.32 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.15 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Popescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.